REAL-WORLD UTILISATION AND CLINICAL OUTCOMES OF PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER TREATED WITH OLAPARIB IN THE FIRST-LINE MAINTENANCE SETTING: 2-YEAR CLINICAL OUTCOMES OF THE PAN-EUROPEAN OVAL-1 STUDY

被引：0

作者：

Lorusso, Domenica ^{[1
,2
]}

Garbay, Delphine ^{[3
]}

Asselain, Bernard Jean Roger ^{[4
]}

Miller, Rowan ^{[5
,6
]}

Raspagliesi, Francesco ^{[7
]}

Zamagni, Claudio ^{[8
]}

Leary, Alexandra ^{[9
]}

Bellier, Charlotte ^{[10
]}

Glasspool, Ros ^{[11
,12
]}

Jayson, Gordon ^{[13
,14
]}

Grevat, Emmanuelle ^{[15
]}

Kertous, Mehdi ^{[15
]}

Sabatucci, Ilaria ^{[16
]}

Padrone, Claudia ^{[16
]}

Jayia, Parveen ^{[17
]}

Hada, Manila ^{[18
]}

Mclaurin, Kimmie ^{[18
]}

Gourley, Charlie ^{[19
]}

机构：

[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Dipartimento Scienze Salute Donna, Bambino & Sanita Pubbl, Rome, Italy

[2] Univ Cattolica Sacro Cuore, Rome, Italy

[3] Clin Tivoli Ducos, Bordeaux, France

[4] ARCAGY GINECO, Paris, France

[5] Univ Coll London Hosp, London, England

[6] St Bartholomews Hosp, London, England

[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[9] Inst Gustave Roussy, Villejuif, France

[10] Ctr Oscar Lambret, Dept Cancerol Gynecol & Senol, Lille, France

[11] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland

[12] Univ Glasgow, Glasgow, Scotland

[13] Univ Manchester, Dept Med Oncol, Christie NHS Fdn Trust, Manchester, England

[14] Univ Manchester, Div Canc Sci, Fac Biol Med & Hlth, Manchester, England

[15] AstraZeneca, Paris, France

[16] AstraZeneca, Milan, Italy

[17] AstraZeneca, London, England

[18] AstraZeneca, Oncol Outcomes Res, Global Med Affairs Evidence Generat & External Al, Gaithersburg, MD USA

[19] Univ Edinburgh, Canc Res UK Scotland Ctr, Edinburgh, Scotland

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷

关键词：

D O I：

10.1136/ijgc-2023-ESGO.895

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

512

引用

页码：A426 / A426

页数：1

共 50 条

[1] REAL-WORLD TREATMENT PATTERNS AND OUTCOMES WITH FIRST-LINE MAINTENANCE OLAPARIB FOR BRCAM ADVANCED OVARIAN CANCER: A PAN-EUROPEAN STUDY (OVAL-1)
Gourley, C.
Asselain, B.
Garbay, D.
Lorusso, D.
Miller, R.
Condon, O.
Kertous, M.
Padrone, C.
Rigney, U.
Dube, S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A204 - A205
[2] Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: US retrospective cohort study.
Eskander, Ramez Nassef
Alam, Naufil
Long, Grainne H.
Ozgoren, Ozan
Ambler, Will
Volpe, Stephanie
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Outcomes of niraparib first-line maintenance among patients with BRCA wild-type advanced ovarian cancer in a real-world clinical setting
Kupets, Rachel
Piedimonte, Sabrina
Clarfield, Lauren
Manley, Mollie
Peragine, Christine
GYNECOLOGIC ONCOLOGY, 2024, 190 : S265 - S266
[4] Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Bellier, Charlotte
Gladieff, Laurence
Le Du, Fanny
Berton, Dominique
Bonnard, Charlotte
Suau, Delphine
Richard, Anne-Celine
Brenner, Ophelie
Lahouegue, Amir
Freyer, Gilles
Floquet, Anne
Frank, Sophie
Kfoury, Maria
DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 207 - 213
[5] Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Charlotte Bellier
Laurence Gladieff
Fanny Le Du
Dominique Berton
Charlotte Bonnard
Delphine Suau
Anne-Céline Richard
Ophélie Brenner
Amir Lahouegue
Gilles Freyer
Anne Floquet
Sophie Frank
Maria Kfoury
Drugs - Real World Outcomes, 2023, 10 : 207 - 213
[6] Real-world experience with a first-line olaparib maintenance monotherapy for advanced BRCA mutated ovarian carcinoma
Skof, Erik
Gregoric, Brigita
Skrbinc, Breda
Jansa, Vid
Cvjeticanin, Branko
Krajec, Maja
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A305 - A305
[7] Real world clinical outcomes of niraparib first line maintenance therapy in patients with BRCA wildtype advanced ovarian cancer
Piedimonte, Sabrina
Clarfield, Lauren
Manley, Mollie
Kupets, Rachel
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A325 - A325
[8] Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau
Cao, Yabing
Chen, Hongtao
Huang, Yaobin
Hu, Hao
CANCER REPORTS, 2019, 2 (05)
[9] Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.
Vasudevan, Anupama
English, Sandy
Gart, Mike
Oladipo, Taofikat
Hartman, John
Iadeluca, Laura L.
Kudrik, Fred J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Real-world clinical outcomes of patients with BRCA-mutated (BRCAm) HER2-negative metastatic breast cancer: A CancerLinQ® study
Miller, Robert S.
Mokiou, Stella
Taylor, Aliki
Jiang, Miao
Sun, Ping
McCutcheon, Susan
CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →